A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Roche
- 24 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Jan 2008 Status changed from recruiting to in progress.
- 19 Aug 2007 Status changed from in progress to recruiting.